Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Period	TotalRevenue
2022-12-31	$110.25M
2023-03-31	$33.20M
2023-06-30	N/A
2023-12-31	$163.91M
2024-12-31	$203.07M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XERS	$6.05	+1.68%	1.03M
3
4
5

Xeris Biopharma Holdings Inc. (XERS) Revenue History

Revenue Data

Get Xeris Biopharma Holdings Inc. Data in Excel

More XERS Financial Data